Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support holding ⢠Overhead supply Support Level: $35.0 / $34.1 Resistance Level: $38.3 - $39.1 Over the last month, CLDX remains in a broader uptrend but has weakened into a short-term pullback, with support at $35.0/$34.1 and a need to reclaim $38-$39 to regain momentum.
Sentiment & News
Key News Insights: ⢠Phase 2 failure ⢠Program discontinued ⢠CFO transition Celldex's barzolvolimab missed Phase 2 endpoints in prurigo nodularis, prompting it to end development in that indication and pressuring shares, while attention shifts to its ongoing late-stage urticaria trials. ŕ´
AI Summary
CLDX has become a far more binary, high-conviction biotech story centered on barzolvolimab's CSU/urticaria readouts: the $345M financing improves runway and lowers near-term funding risk, but with prurigo nodularis already failed and the stock looking valuation-sensitive, upside now depends on clean late-stage execution rather than broad pipeline optionality.
Description
Celldex Therapeutics is a biopharmaceutical company developing monoclonal and bispecific antibody therapies for inflammatory conditions and various cancers. Its clinical pipeline includes programs directed at KIT, CD40 and a bispecific combining PD-L1 blockade with CD27 costimulation, among other antibody candidates. The company maintains research and licensing relationships with academic institutions and Amgen, and is headquartered in Hampton, New Jersey, having been incorporated in 1983.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 26 | Mar 5 | CLDX | Celldex Therapeutics, Inc. | Completion of enrollment in two global Phase 3 EMBARQ-CSU trials and multiple Phase 2 data presentations at AAAAI (Feb 27âMar 2) have ignited a ~35% short-term rally; near-term scientific disclosures can drive further spikes, making CLDX a tactically attractive, event-driven biotech trade. | Closed | -4.2% |